(190 days)
None
No
The summary describes a standard lithotripsy device using electromagnetic shock waves and imaging for targeting, with no mention of AI or ML in the device description, intended use, or performance studies.
Yes
The device is indicated for the fragmentation of kidney stones, which is a treatment for a medical condition.
No
The device is a Lithotripter, used for fragmenting kidney stones. While it uses imaging (X-ray and ultrasound) for patient positioning and monitoring, its primary function is therapeutic (fragmentation), not diagnostic.
No
The device description clearly outlines multiple hardware components including a shockwave generator, operator interface (industrial computer with dual monitors), water circulation subsystem, and patient handling subsystem, in addition to requiring external imaging devices (C-arm X-ray and/or ultrasound).
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices intended to be used in vitro for the examination of specimens, including blood and tissue samples, derived from the human body, solely or principally for the purpose of providing information concerning a physiological or pathological state, or a congenital abnormality, or to monitor therapeutic measures.
- Device Function: The Lite-Med LM-9300 ELMA Lithotripter is a device that uses extracorporeal shock waves to fragment kidney and ureteral stones within the patient's body. It is a therapeutic device, not a diagnostic one.
- Intended Use: The intended use clearly states fragmentation of stones in vivo.
- Device Description: The description details the mechanism of generating and focusing shock waves for treatment, not for analyzing biological samples.
- Imaging Modality: While it uses imaging (X-ray and ultrasound), these are for guiding the treatment and positioning the patient, not for analyzing biological specimens.
The device is a therapeutic medical device used for treating kidney and ureteral stones.
N/A
Intended Use / Indications for Use
The Lite-Med LM-9300 ELMA Lithotripter is indicated for fragmentation of kidney stones such as renal calyx stones and renal pelvic stones and for upper, middle and lower ureteral stones by extracorporeal shock wave lithotripsy (ESWL).
Product codes
LNS
Device Description
The Lite-Med LM-9300 ELMA is an Electromagnetic Extracorporeal Shock Wave Lithotripter that effectively treats urinary calculi. It is routinely used for the fragmentation of kidney and ureteral stones and offers a good combination of clinical performance, flexibility and affordability. The standard LM-9300 ELMA system consists of a shockwave generator, an operator interface (industrial computer with dual monitors), a water circulation subsystem and a patient handling subsystem. For the Extracorporeal Shock Wave Lithotripsy (ESWL) operation to be fully functional, one or two more subsystems are necessary. The first is a C-arm X-ray fluoroscopy device and the second is an ultrasound imaging unit. Normally one of the imaging devices is sufficient. For most advanced ESWL designs such as LM-9300 ELMA both X-ray and ultrasound are used for patient positioning and monitoring purposes.
Shock waves are generated on the basis of a principle similar to that used in loudspeakers. An electrical impulse is sent through an inductance coil, generating a magnetic field which repulses a metallic membrane. The acoustic impulse created by this repulsion is focused by an acoustic lens to form a shock wave. A water circulation subsystem is used to provide transmission of shockwaves and cooling of the generator.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
C-arm X-ray fluoroscopy device, ultrasound imaging unit
Anatomical Site
Kidney, ureteral
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The clinical investigations are performed at 2 sites with 1, 2, and 4 weeks follow-up to support this application. A total of 44 patients with 44 stones were treated. 31 patients were males and 13 patients were females. The stones sizes treated were between 5 mm and 16 mm. None of the patients received general anesthesia. The averaged stone-free ratio at one month after the stone treatments of the investigations is 80%. Among the investigations with residual fragments remained at 1 month after the treatments, more than half of the stone fragments are less than 5mm x 4mm in size. This means that the effectiveness of the LM-9300 ELMA Lithotripter is better than 90% .
Key Metrics
Averaged stone-free ratio at one month after the stone treatments of the investigations is 80%. The effectiveness of the LM-9300 ELMA Lithotripter is better than 90%.
Predicate Device(s)
Lite-Med LM-9200 ELMA (K103217), Dornier Compact Alpha (K002929), Siemens Lithoskop (K070665)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5990 Extracorporeal shock wave lithotripter.
(a)
Identification. An extracorporeal shock wave lithotripter is a device that focuses ultrasonic shock waves into the body to noninvasively fragment urinary calculi within the kidney or ureter. The primary components of the device are a shock wave generator, high voltage generator, control console, imaging/localization system, and patient table. Prior to treatment, the urinary stone is targeted using either an integral or stand-alone localization/imaging system. Shock waves are typically generated using electrostatic spark discharge (spark gap), electromagnetically repelled membranes, or piezoelectric crystal arrays, and focused onto the stone with either a specially designed reflector, dish, or acoustic lens. The shock waves are created under water within the shock wave generator, and are transferred to the patient's body using an appropriate acoustic interface. After the stone has been fragmented by the focused shock waves, the fragments pass out of the body with the patient's urine.(b)
Classification. Class II (special controls) (FDA guidance document: “Guidance for the Content of Premarket Notifications (510(k)'s) for Extracorporeal Shock Wave Lithotripters Indicated for the Fragmentation of Kidney and Ureteral Calculi.”)
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, overlapping each other to create a sense of depth and connection.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 20, 2015
Lite-Med, Inc. Walt Hsu President & CEO 9th Floor, 49 Dongxing Road Xinyi District, Taipei City 11070 Taiwan
Re: K142561
Trade/Device Name: LM-9300 ELMA Regulation Number: 21 CFR 876.5990 Regulation Name: Extracorporeal shockwave lithotripter Regulatory Class: II Product Code: LNS Dated: December 22, 2014 Received: February 18, 2015
Dear Walt Hsu,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Joyce M. Whang -S
for Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use Statement Section 4.
510k Number: K142561
Indications for Use
510(k) Number (if known): K142561 Device Name: LM-9300 ELMA Indications for Use:
The Lite-Med LM-9300 ELMA Lithotripter is indicated for fragmentation of kidney stones such as renal calyx stones and renal pelvic stones and for upper, middle and lower ureteral stones by extracorporeal shock wave lithotripsy (ESWL).
Prescription Use AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use ______ (21 CFR 801 Subpart C )
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
3
Section 5. 510(k) Summary
510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
LITE-MED LM-9300 ELMA Lithotripter
In response to the Safe Medical Devices Act of 1990, the following is a summary of the safety and effectiveness information upon which the substantial equivalence determination is based.
The safety and effectiveness of the LM-9300 ELMA is based upon a determination of the substantial equivalence as well as the safety and effectiveness of its predicate devices, which includes the following: Lite-Med LM-9200 ELMA (K103217), Dornier Compact Alpha (K002929), and Siemens Lithoskop (K070665).
Applicant/Manufacturer Information
Lite-Med Inc. 9th Floor, 49 Dongxing Road, Xinyi District Taipei City. Taiwan. Zip code: 11070 Contact Person: Walt Hsu Tel: +886-2-2915-4183 Fax: +886-2-2911-1780
Device Identification
Proprietary Trade Name: LM-9300 ELMA Generic Device Name: Extracorporeal Shockwave Lithotripter Product Code: 78 LNS Regulatory Class: Class II with special controls Regulation Number: 21 CFR 876.5990
4
Intended Use
The Lite-Med LM-9300 ELMA Lithotripter is indicated for fragmentation of kidney stones such as renal calyx stones and renal pelvic stones and for upper, middle and lower ureteral stones by extracorporeal shock wave lithotripsy (ESWL).
Substantial Equivalence
The Lite-Med LM-9300 ELMA Lithotripter is substantially equivalent to the following currently marketed devices:
Lite-Med LM-9200 ELMA (K103217) Dornier Compact Alpha (K002929) Siemens Lithoskop (K070665)
Device Description
The Lite-Med LM-9300 ELMA is an Electromagnetic Extracorporeal Shock Wave Lithotripter that effectively treats urinary calculi. It is routinely used for the fragmentation of kidney and ureteral stones and offers a good combination of clinical performance, flexibility and affordability. The standard LM-9300 ELMA system consists of a shockwave generator, an operator interface (industrial computer with dual monitors), a water circulation subsystem and a patient handling subsystem. For the Extracorporeal Shock Wave Lithotripsy (ESWL) operation to be fully functional, one or two more subsystems are necessary. The first is a C-arm X-ray fluoroscopy device and the second is an ultrasound imaging unit. Normally one of the imaging devices is sufficient. For most advanced ESWL designs such as LM-9300 ELMA both X-ray and ultrasound are used for patient positioning and monitoring purposes.
Shock waves are generated on the basis of a principle similar to that used in loudspeakers. An electrical impulse is sent through an inductance coil, generating a magnetic field which repulses a metallic membrane. The acoustic impulse created by this repulsion is focused by an acoustic lens to form a shock wave. A water circulation subsystem is used to provide transmission of shockwaves and cooling of the generator.
Technological Characteristics
The shock wave characteristics are reported below by taking the guideline described in the consensus standard IEC 61846 "Ultrasonics - Pressure pulse lithotripters - Characteristics of fields" (1998) into consideration. PVDF film type hydrophones are used in the measurements. The details of the measurements/calculations are given in relevant part of 510(k) application. The results are found similar to the predicate device characteristics.
5
| Parameter | min(16kv) | typical(18kv) | max(20kv) |
|---|---|---|---|
| Peak-positive acoustic pressure(MPa) | 24.7 | 41.1 | 46.9 |
| Peak-negative acoustic pressure(MPa) | 2.5 | 2.5 | 2.9 |
| Rise time (ns) | 400 | 200 | 100 |
| Compressional pulse duration(ns) | 400 | 400 | 360 |
| Maximum focal width(mm) | 5 | 5 | 8 |
| Orthogonal focal width(mm) | 5 | 5 | 8 |
| Focal extent(mm) | 90 | 90 | 90 |
| Focal volume(mm3) | 1178 | 1178 | 3016 |
| Distance between the focus and target | |||
| location(mm) -z-axis | 3 | 3 | 3 |
| Distance between the focus and target | |||
| location(mm) -x/y-axis | 2 | 2 | 2 |
| Derived focal acoustic pulse energy | |||
| density (mJ/mm²) | 0.23 | 0.48 | 0.78 |
| Derived focal acoustic pulse energy(mJ) | 1.48 | 3.19 | 7.05 |
Clinical Studies
The clinical investigations are performed at 2 sites with 1, 2, and 4 weeks follow-up to support this application. A total of 44 patients with 44 stones were treated. 31 patients were males and 13 patients were females. The stones sizes treated were between 5 mm and 16 mm. None of the patients received general anesthesia. The averaged stone-free ratio at one month after the stone treatments of the investigations is 80%. Among the investigations with residual fragments remained at 1 month after the treatments, more than half of the stone fragments are less than 5mm x 4mm in size. This means that the effectiveness of the LM-9300 ELMA Lithotripter is better than 90% .
Safety and Performance Studies
The LM-9300 ELMA is designed in accordance with the product safety and performance requirements established in the following standards given below:
| IEC 60601-2-36 | Particular Requirements for safety of equipment for
extracorporeally induced lithotripsy |
|----------------|------------------------------------------------------------------------------------------------------------------|
| IEC 61846 | Ultrasonics – Pressure pulse lithotripters – Characteristics of
fields |
| IEC 60601-1 | Medical Electrical Equipment – Part 1 General Requirements for
basic safety and essential performance |
| IEC 60601-1-2 | Medical Electrical Equipment – Part 1 General Requirements for
Safety-2. Collateral Standard: Electromagnetic |
6
| Compatibility-Requirements and Tests | |
|---|---|
| ISO 13485 | Medical Devices – Quality Management Systems – |
| Requirements for Regulatory Purposes | |
| ISO 14971 | Medical Devices – Application of Risk Management to Medical |
| Devices | |
| IEC 60601-1-3 | Medical Electrical Equipment – Part 1 General Requirements for |
| Radiation Protection in Diagnostic X-Ray Equipment | |
| IEC 60601-2-54 | Medical Electrical Equipment – Part 2 Particular Requirements |
| for the basic safety and essential performance of X-ray | |
| equipment for Radiography and Radioscopy |
Conclusion
From a clinical perspective and comparing design specifications, the LM-9300 ELMA is substantially equivalent to its predicate devices. The LM-9300 ELMA meets the FDA requirements stated in "Guidance for the Content of Premarket Notifications 510(k) for Extracorporeal Shock Wave Lithotripters Indicated for the Fragmentation of Kidney and Ureteral Calculi" issued on Aug. 9, 2000. Lite-Med Inc. believes the minor differences of the LM-9300 ELMA and its predicate devices should not raise any concerns regarding the overall safety or effectiveness.